On CNBC's “Halftime Report Final Trades ,” Jim Lebenthal of Cerity Partners said he is long-term bullish but a bit nervous ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $502.55, marking a +0.45% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.33%. At the ...

Vertex's cloud growth momentum remains strong, with a 27% y/y increase in 4Q24. Read more to see why I upgrade VERX stock ...

Celebrating the best wholesale brokers in the USA who have been selected by the nation’s brokers for their ability to place ...

Note: All prices are listed in SGD. Where applicable, fees are for only trading SGX-listed stocks. This means prices may vary for U.S.-listed stocks and Hong Kong-listed stocks, for example. All cash ...

Asana (NYSE:ASAN – Get Free Report) had its price target dropped by equities researchers at Jefferies Financial Group from $19.00 to $15.00 in a note issued to investors on Tuesday,Benzinga reports.

What is the current share price of Vertex Pharmaceuticals (VRTX)? Vertex Pharmaceuticals's (VRTX) current share price is $488.25. This constitutes a price movement of 0.99% when compared to the share ...

In this article, we will look at the 11 Best Pharma Stocks to Buy According to Hedge Funds. Why is China the Talk of the Town in the Pharma Industry? The US pharmaceutical sector is experiencing a ...

Vikki Velasquez is a researcher and writer who has managed, coordinated, and directed various community and nonprofit organizations. She has conducted in-depth research on social and economic ...

Vertex Pharmaceuticals' products are constantly in high demand. The company's portfolio should help drive revenue growth for a while. It also has an exciting pipeline that will help it diversify ...

Here we highlight a subset of our preferred stocks from the screener. Overview: Vertex, Inc. offers enterprise tax technology solutions for retail, wholesale, and manufacturing sectors both in the ...

Currently Managing Director of Motley Fool Money, Brendan has worked full-time for The Motley Fool since 2011. He has written hundreds of articles for The Motley Fool and provided analysis on TV ...